Previous 10 | Next 10 |
2023-05-31 08:32:12 ET Belite Bio ( BLTE ) -37% commences public offering of American Depositary Shares of $30M. Advance Auto Parts ( AAP ) -27% after Q1 earning release . Ambarella ( AMBA ) -20% after Q1 earning release . FG Financial Group (FG...
2023-05-30 10:01:01 ET Gainers: HeartBeam ( BEAT ) +23% . Taro Pharmaceutical Industries ( TARO ) +22% . Akebia Therapeutics ( AKBA ) +19% . Corvus Pharmaceuticals ( CRVS ) +16% . Immix Biopharma ( IMMX ) +13% . Losers:...
2023-05-30 09:03:45 ET HeartBeam ( NASDAQ: BEAT ) is trading 35% higher premarket after it had entered into a strategic alliance with Samsung to revolutionize cardiac diagnostics. The partnership combines HeartBeam's expertise in cardiac assessment and monitoring with Sams...
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform intended for patient use at home, today announced that it has entered into a Strategic Alliance Agreement (SAA) with Samsung, extending the existing SAA...
2023-05-25 10:04:19 ET Gainers: Absci ( ABSI ) +17% . Predictive Oncology ( POAI ) +10% . Cardio Diagnostics ( CDIO ) +8% . Ocean Biomedical ( OCEA ) +8% . HeartBeam ( BEAT ) +7% . Losers: Annexon ( ANNX ) -57% ....
Patent Underscores AI for Vectorcardiography (VECG) IP Leadership Effort HeartBeam, Inc . (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform intended for patient use at home, today announced it has received ...
HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA...
2023-05-18 09:11:02 ET HeartBeam ( NASDAQ: BEAT ) has submitted a marketing application to the FDA for its HeartBeam AIMIGo System. The AIMIGo System is a personal, portable VECG solution for assessing cardiac symptoms. It utilizes a reusable VECG recording device and clou...
Submission Seeks Clearance for the Company’s 3D Vector Electrocardiogram Device HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform intended for patient use at home, today announced it ...
2023-05-14 05:21:09 ET HeartBeam, Inc. (BEAT) Q1 2023 Earnings Conference Call May 11, 2023 04.30 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Rob Eno - President Richard Brounstein - Chief Financial Officer Conference C...
News, Short Squeeze, Breakout and More Instantly...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has been added to the Russell Microcap(R) Index. The move was effective after market close on June 28, 2024, and is part of FTSE Russell’s annual reconst...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that it has been added to the Russell Microcap® Index effective after the market close on June 28, 2024 as part of FTSE Russell...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel o...